Adipo Therapeutics completed a $1.9M seed funding bridge to advance the development of its lead asset ADPO-002 for the treatment of obesity through increased energy expenditure.
Adipo Therapeutics completed a $1.9M seed funding bridge to advance the development of its lead asset ADPO-002 for the treatment of obesity through increased energy expenditure.
03/07/24, 1:34 PM
Location
indianapolisMoney raised
$1.9 million
Industry
biopharma
therapeutics
health care
biotechnology
Round Type
seed
Investors
Vision Tech Partners, Iu Ventures, Elevate Ventures, Purdue Research Foundation
Adipo Therapeutics, a late-stage, preclinical biopharmaceutical company focusing on treatments for obesity and Type 2 diabetes, has completed a $1.9 million seed funding bridge, bringing its total seed funding to $4 million. The funding will be used to complete critical studies to demonstrate ADPO-002's potential in converting energy-storing white adipose tissue to energy-burning brown adipose tissue in human fat. Key investors in Adipo include Purdue Research Foundation, Elevate Ventures, IU Ventures, and VisionTech Partners.
Company Info
Location
1210 waterway blvd.
indianapolis, indiana, united states
Additional Info
Adipo Therapeutics, an Indiana biotechnology company, is developing polymer-based, Notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue to induce browning, or white-to-beige adipocyte transformation.